Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study

Shun Kohsaka(Keio University), Dianna J. Magliano(Baker Heart and Diabetes Institute)
The Lancet Diabetes & Endocrinology
June 16, 2020
Cited by 93


Related Papers